Get the Stockscreener App
1.63
0.00%
0.00
After Hours:
1.65
0.02
+1.23%
Werewolf Therapeutics Inc stock is traded at $1.63, with a volume of 895.62K.
It is up +0.00% in the last 24 hours and up +13.99% over the past month.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
See More
Previous Close:
$1.63
Open:
$1.64
24h Volume:
895.62K
Relative Volume:
1.43
Market Cap:
$74.54M
Revenue:
$19.94M
Net Income/Loss:
$-37.37M
P/E Ratio:
-1.5673
EPS:
-1.04
Net Cash Flow:
$-33.38M
1W Performance:
-19.70%
1M Performance:
+13.99%
6M Performance:
+129.58%
1Y Performance:
-18.50%
1-Day Range:
$1.56
$1.6965
1-Week Range:
$1.56
$2.13
52-Week Range:
$0.595
$4.18
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
Name
Werewolf Therapeutics Inc
Sector
Industry
Phone
617-952-0555
Address
200 TALCOTT AVENUE, WATERTOWN
Compare HOWL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOWL
Werewolf Therapeutics Inc
|
1.63 | 74.54M | 19.94M | -37.37M | -33.38M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-24 | Initiated | JMP Securities | Mkt Outperform |
| Aug-24-23 | Initiated | Wedbush | Outperform |
| Jun-06-23 | Resumed | Jefferies | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-25-21 | Initiated | Evercore ISI | Outperform |
| May-25-21 | Initiated | H.C. Wainwright | Buy |
| May-25-21 | Initiated | Jefferies | Buy |
| May-25-21 | Initiated | SVB Leerink | Outperform |
View All
Werewolf Therapeutics Inc Stock (HOWL) Latest News
Analyzing recovery setups for Werewolf Therapeutics Inc. investorsJuly 2025 News Drivers & AI Based Buy/Sell Signal Reports - newser.com
How to recover losses in Werewolf Therapeutics Inc. stockJuly 2025 Retail & Risk Adjusted Buy/Sell Alerts - newser.com
Will Werewolf Therapeutics Inc. stock maintain dividend yieldQuarterly Portfolio Report & AI Enhanced Trade Execution Alerts - newser.com
Using data tools to time your Werewolf Therapeutics Inc. exit2025 Top Gainers & Fast Entry Momentum Alerts - newser.com
Weiss Ratings Reaffirms "Sell (D-)" Rating for Werewolf Therapeutics (NASDAQ:HOWL) - MarketBeat
How high can Werewolf Therapeutics Inc. stock goEarnings Summary Report & Reliable Intraday Trade Alerts - newser.com
Werewolf Therapeutics receives FDA Fast Track for melanoma therapy By Investing.com - Investing.com Nigeria
Werewolf Therapeutics Says Investigational Melanoma Therapy WTX-124 Receives US FDA Fast Track Designation - MarketScreener
Werewolf Therapeutics receives FDA Fast Track for melanoma therapy - Investing.com
Werewolf Therapeutics receives fast track designation from the U.S. FDA for WTX-124, an investigational therapy for the treatment of cancer - MarketScreener
Werewolf Therapeutics Receives Fast Track Designation from - GlobeNewswire
Fast Track for WTX-124: Werewolf advances IL-2 INDUKINE for relapsed cutaneous melanoma - Stock Titan
Werewolf Therapeutics Faces Nasdaq Compliance Challenge - TipRanks
Werewolf Therapeutics notifies Nasdaq of audit committee noncompliance after board member’s passing - Investing.com
Using flow based indicators on Werewolf Therapeutics Inc.Market Growth Summary & Risk Managed Trade Strategies - newser.com
Will earnings trigger a reversal in Werewolf Therapeutics Inc.2025 Institutional Moves & Long-Term Safe Investment Ideas - newser.com
Werewolf Therapeutics Inc. stock chart pattern explainedWeekly Trade Report & AI Enhanced Trade Execution Alerts - newser.com
Intraday pattern recognizer results for Werewolf Therapeutics Inc.Fed Meeting & Weekly High Return Stock Forecasts - newser.com
Jefferies Initiates Werewolf Therapeutics(HOWL.US) With Buy Rating, Announces Target Price $4 - 富途牛牛
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting - GlobeNewswire
Werewolf Therapeutics to Present Innovative Research at SITC 40th Annual Meeting - Quiver Quantitative
3 Posters: Werewolf Therapeutics to Present WTX-124, mWTX-330 Research at SITC Nov 5-9 - Stock Titan
Published on: 2025-09-30 05:19:05 - newser.com
Goldman Sachs Group Inc. Has $109,000 Stock Holdings in Werewolf Therapeutics, Inc. $HOWL - Defense World
Published on: 2025-09-30 01:50:53 - newser.com
What analysts say about Werewolf Therapeutics Inc stockMomentum Trading Signals & Outstanding Growth Stocks - earlytimes.in
Earnings visualization tools for Werewolf Therapeutics Inc.Portfolio Performance Summary & Fast Moving Stock Trade Plans - newser.com
Werewolf Therapeutics Inc Stock (HOWL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Werewolf Therapeutics Inc Stock (HOWL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
May 14 '25 |
Buy |
0.98 |
162,539 |
159,288 |
6,237,482 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
May 13 '25 |
Buy |
0.98 |
52,974 |
51,915 |
6,074,943 |
| MPM BioVentures 2014, L.P. | 10% Owner |
Mar 27 '25 |
Sale |
1.05 |
1,963 |
2,061 |
3,208,793 |
| EVNIN LUKE | Director |
Mar 27 '25 |
Sale |
1.05 |
2,425 |
2,546 |
4,309,860 |
| GADICKE ANSBERT | 10% Owner |
Mar 27 '25 |
Sale |
1.05 |
4,386 |
4,605 |
6,718,670 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):